The “marketing authorization suspension procedure“will begin in three months, announced Pr. Dominique Maraninchi, Director General of the National Agency for the Safety of Medicines and Health Products (ANSM), who recommended that patients not abruptly stop their treatment in the meantime. and consult a dermatologist or gynecologist.
